THE INDIAN PHARMACIST Official Circular Pharmacy Logo THE INDIAN PHARMACISTLearn. Explore. Practise. Excel.
MEDICINE MONOGRAPH CODE: [6.6] ID: TIP-MED-000452 ⚠️ HIGH-ALERT / SPECIALIST SUPERVISION

Other Commonly Used Hormonal Medicines (Deflazacort, Dexamethasone, Fludrocortisone, & Gynaecological Progestogens)

Active Ingredient / Scientific Identity: Other Commonly Used Hormonal Medicines • Class: Systemic Glucocorticoids (Deflazacort, Dexamethasone), Mineralocorticoid (Fludrocortisone), and Oral Progestogens (Norethisterone, Medroxyprogesterone)

⚖️ Compare Profile
Generic / Entity NameOther Commonly Used Hormonal Medicines (Deflazacort, Dexamethasone, Fludrocortisone, & Gynaecological Progestogens) ([6.6])
Verified Indian Brands / RefGeneric Compendial Entry (No Commercial Brand Claimed)
Pharmacological ClassSystemic Glucocorticoids (Deflazacort, Dexamethasone), Mineralocorticoid (Fludrocortisone)
Available Dosage FormsStandard hospital formulary strengths
Regulatory ClassificationSchedule G / Schedule H (Medical Supervision Mandatory)
Key Warning & Review DateHigh-alert hospital specialist agent; administer under close physiological and laboratory monitoring.
Reviewed: 2026-11-10
Safety Matrix:⚖️ Legal Status: Schedule G / Schedule H (Medical Supervision Mandato🚨 Clinically High-Alert: Independent Dose & Route Verification Required👨‍⚕️ Specialist-Supervised Therapy

1. Clinical & Scientific Overview

Other Commonly Used Hormonal Medicines (Deflazacort, Dexamethasone, Fludrocortisone, & Gynaecological Progestogens) (TIP-MED-000452, Reference Code [6.6]) is classified under Endocrine & Hormonal Medicines as a Systemic Glucocorticoids (Deflazacort, Dexamethasone), Mineralocorticoid (Fludrocortisone), and Oral Progestogens (Norethisterone, Medroxyprogesterone). Within the Indian regulatory and compendial framework, it is governed under Schedule G / Schedule H (Medical Supervision Mandatory).

Verified Indian Market Examples / Compendial Status:
Representative Indian Formulations (for identification only): Deflazacort: Defcort (Macleods), Dezacor, Orthocort (1 mg, 6 mg, 12 mg, 24 mg, 30 mg). Dexamethasone: Dexona (Zydus—0.5 mg, 4 mg), Decdan. | Strengths: Deflazacort Tablets: 6 mg, 12 mg, 24 mg, 30 mg; Dexamethasone Tablets: 0.5 mg, 4 mg, 8 mg & Injection 4 mg/mL; Fludrocortisone Tablets: 0.1 mg (100 mcg); Norethisterone Tablets: 5 mg, 10 mg CR;
Representative Indian Formulations (for identification only): Deflazacort: Defcort (Macleods), Dezacor, Orthocort (1 mg, 6 mg, 12 mg, 24 mg, 30 mg). Dexamethasone: Dexona (Zydus—0.5 mg, 4 mg), Decdan. | Strengths: Deflazacort Tablets: 6 mg, 12 mg, 24 mg, 30 mg; Dexamethasone Tablets: 0.5 mg, 4 mg, 8 mg & Injection 4 mg/mL; Fludrocortisone Tablets: 0.1 mg (100 mcg); Norethisterone Tablets: 5 mg, 10 mg CR;
Dosage Forms & Available Strengths:
Standard hospital formulary strengths
Routes: Intravenous / Parenteral / Oral

3. Mechanism of Action & Pharmacodynamics

Established pharmacological class action (Systemic Glucocorticoids (Deflazacort, Dexamethasone), Mineralocorticoid (Fludrocortisone), and Oral Progestogens (Norethisterone, Medroxyprogesterone)): targets primary receptor, enzyme, ion-channel, or cellular pathway to achieve therapeutic efficacy in • Deflazacort: Oxazoline derivative of prednisolone (6 mg Deflazacort = 5 mg Prednisolone) used in rheumatoid arthritis, asthma, nephrotic syndrome, and Duchenne muscular dystrophy (slightly lower diabetogenic and bone loss profile at equipotent doses, though all steroid precautions still apply).

4. Therapeutic Indications & Evidence-Supported Uses

  • • Deflazacort: Oxazoline derivative of prednisolone (6 mg Deflazacort = 5 mg Prednisolone) used in rheumatoid arthritis, asthma, nephrotic syndrome, and Duchenne muscular dystrophy (slightly lower diabetogenic and bone loss profile at equipotent doses, though all steroid precautions still apply)

🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.

5. Educational Dosage Context, Formulations & Administration

Educational Dosing & Regimen Summary: General Adult Reference: Deflazacort: 6 mg–30 mg OD after breakfast. Dexamethasone: 0.5 mg–8 mg/day after breakfast. Fludrocortisone: 50 mcg–200 mcg (0.5 to 2 tablets of 0.1 mg) once daily in the morning. Norethisterone: 5 mg twice or three times daily for 5–21 days per gynaecologist schedule. (Duration: Strictly per indication; taper Deflazacort/Dexamethasone if used >2 weeks. For Norethisterone/Medroxyprogesterone in AUB, complete the exact 5-, 10-, or 21-day cycle (withdrawal bleeding normally occu.)

Administration & Meal Timing: Oral (PO), Parenteral (IV / IM / SC as specified) | Food & Meal Timing: Take with or after meals (especially breakfast for corticosteroids) to prevent gastric irritation. | Best Time of Day: Corticosteroids & Fludrocortisone: Once daily in the morning after breakfast. Progestogens (Norethisterone/Medroxyprogesterone): Divided 2–3 times daily or once daily at the same c.

6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment

Absorption & Disposition:
Hospital pharmacokinetic profile; monitor therapeutic response and organ clearance.
Metabolism & Biotransformation:
Renal: Monitor fluid retention and BP with Fludrocortisone and steroids in CKD. Hepatic: Oral progestogens (Norethisterone/Meprate) are contraindicated in severe hepatic dysfunction or active jaundice.
Elimination & Renal Adjustment:
Renal: Monitor fluid retention and BP with Fludrocortisone and steroids in CKD. Hepatic: Oral progestogens (Norethisterone/Meprate) are contraindicated in severe hepatic dysfunction or active jaundice.
Hepatic Impairment Considerations:
Renal: Monitor fluid retention and BP with Fludrocortisone and steroids in CKD. Hepatic: Oral progestogens (Norethisterone/Meprate) are contraindicated in severe hepatic dysfunction or active jaundice.

7. Contraindications, Precautions & High-Risk Warnings

Contraindications & Red-Flag Precautions:
  • Glucocorticoids: Same precautions as Prednisolone (hyperglycaemia, GI ulceration with NSAIDs, osteoporosis, infection, HPA suppression—note that Dexamethasone has a 36–54 hour biological half-life and strongly suppresses the HPA axis!)
  • Fludrocortisone: Contraindicated in congestive heart failure and uncontrolled severe hypertension

Key Clinical Precautions: High-alert hospital specialist agent; administer under close physiological and laboratory monitoring.

8. Adverse Effects Profile

Common & Mechanism-Related Adverse Effects:
  • Deflazacort/Dexamethasone: Hyperglycaemia, insomnia, dyspepsia, Cushingoid changes
  • Fludrocortisone: Sodium/water retention, ankle oedema, supine hypertension, hypokalaemia
Serious / Dose-Limiting Adverse Effects:
  • Monitor for hemodynamic instability, organ toxicity, or severe hypersensitivity.

9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions

  • CYP3A4 inducers (rifampicin, phenytoin, carbamazepine) accelerate clearance of dexamethasone, deflazacort, and progestogens
  • NSAIDs + glucocorticoids cause peptic ulceration
  • Fludrocortisone + loop/thiazide diuretics cause profound hypokalaemia

10. Clinical Monitoring, Patient Counselling & Storage

Clinical & Laboratory Monitoring: Continuous clinical, hemodynamic, and organ-function laboratory monitoring.

Pharmacist Patient Counselling Points:

  • • Steroid Potency Equivalence Check: Ensure patients and staff know that 6 mg Deflazacort = 5 mg Prednisolone = 4 mg Methylprednisolone = 0
  • 75 mg Dexamethasone —never confuse mg strengths across steroids! • Floricot Storage Alert: Some Fludrocortisone brands require refrigerator storage (2°C–8°C) or cool storage ( • Primolut-N / Meprate C

Storage, Stability & Dispensing Safeguards: Store in original moisture-protected packaging below 25°C–30°C (or 2°C–8°C cold chain if parenteral/biological vial specified in strengths: Deflazacort Tablets: 6 mg, 12 mg, 24 mg, 30 mg; Dexamethasone Tablets: 0.5 mg, 4 mg, 8 mg & Injection 4 mg/mL; Fludrocortisone Tablets: 0.1 mg (100 mcg); Norethisterone Tablets: 5 mg, 10 mg CR;). Missed-Dose Rule: Take as soon as remembered on the same day. For Norethisterone in Abnormal Uterine Bleeding, missing even 1–2 doses causes immediate breakthrough vaginal bleeding—maintain strict 8- or 12-hourly clock.

11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)

THE 12-STEP ORAL DRUG JOURNEY THROUGH THE HUMAN BODY (LADME) Note: IV bolus enters Step 6 directly (F = 100%); Sublingual & Transdermal routes bypass Step 4–5 Portal First-Pass Metabolism 1. Oral Administration • Tablet / Capsule swallowed • Gastric emptying to duodenum pH 1.5–3.5 (Stomach) 2. Disintegration & Dissolution • Tablet breaks into granules • API dissolves in GI fluid Noyes-Whitney Dissolution Rate 3. GI Epithelial Absorption • Crosses intestinal villi • Passive / Active / P-gp efflux Small Intestine (Large Surface Area) 4. Portal Circulation • Mesenteric veins → Portal vein • Delivers blood to liver sinusoids Pre-systemic Venous Conduit 5. First-Pass Metabolism • Gut & hepatic CYP450 extraction • High: GTN, Propranolol, Morphine Determines Bioavailability (F = f_a × (1-E_H)) 6. Systemic Circulation • Hepatic vein → IVC → Heart • Unbound vs Albumin-bound drug Only FREE drug is active 7–8. Tissue Distribution (Vd) • Capillary permeation to organs • Blood-Brain & Placental barriers Vd = Dose / C_0 (L or L/kg) 9. Target Site of Action • Receptors (GPCR, Ion channel) • Enzymes & Carrier Transporters Pharmacodynamic Effect (E_max, EC50) 10. Hepatic Biotransformation • Phase I (CYP450 Oxidation/Hydrolysis) • Phase II (Glucuronidation/Sulfation) Converts lipophilic drug → hydrophilic metabolite 11. Renal & Biliary Elimination • Nephron: Filtration + Secretion − Reabsorption • Biliary excretion & Enterohepatic recycling Total Clearance CL_tot = CL_renal + CL_hepatic 12. Excretion from the Body • Urine (Primary polar metabolite route) • Bile/Faeces, Expired Air, Sweat, Milk Elimination Half-Life t1/2 = (0.693 × Vd) / CL
svg-v339-01-adme-12-step-journey — 8.1 Complete 12-Step Journey of an Orally Administered Drug (ADME): Figure 8.1: The 12-step physiological journey of a typical orally administered solid dosage form through Liberation, Absorption, Distribution, Metabolism, and Excretion (LADME). Note: Parenteral (IV), sublingual, and inhalational routes bypass gastrointestinal absorption and/or hepatic first-pass metabolism.

12. Authoritative References, Regulatory Sources & Editorial Disclaimer

Primary Compendial & Guideline Reference: Indian Pharmacopoeia (IP 2022) • NFI • CDSCO • NCBI Bookshelf

Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)

Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: VERIFIED_EDUCATIONAL_CONTENT

Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.